NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Type 2 Diabetes
Date of first enrollment	08/07/2010
Target sample size	216
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : LAF237 INN of investigational material : Vildagliptin Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : Oral

Outcome(s)

Primary Outcome	Safety
Secondary Outcome	HbA1c, fasting plasma glucose, fasting insulin, fasting c-peptide, HOMA-B

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	Not applicable
Gender	Both
Include criteria	- Patients with type 2 diabetes inadequately controlled with diet, exercise and metformin, thiazolidinedione, or alpha-GI, or glinides monotherapy - Age in the 20 years or over inclusive - HbA1c in the range of >= 6.5 to =< 10%
Exclude criteria	- Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes - Significant heart diseases - Significant diabetic complications